白云山(00874.HK)吐逾7%重失50天线 澄清复方板蓝根不会对经营业绩构成重大影响
白云山(00874.HK)发通告澄清复方板蓝根不会对经营业绩构成重大影响。该股扭转上周五(16日)急弹13%强势,重失50天及100天线(20.5元及21.1元),最低见20元,现造20.2元,回吐7.1%,成交498万股。
内媒上周尾引述钟南山研究团队发现,白云山复方板蓝根颗粒对新冠病毒有效。不过,白云山发通告澄清指,有关媒体报道所涉及相关结论只是针对公司合营企业白云山和黄公司复方板蓝根颗粒开展的抗新冠病毒体外筛选实验结果,後续还需对该产品开展进一步相关工作,相关工作尚存在一定不确定性,而且复方板蓝根颗粒销售预计不会对公司经营业绩构成重大影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.